AVENUE THERAPEUTICS, INC.
AVENUE THERAPEUTICS, INC. (ATXI): 9 pipeline candidates · 2 upcoming catalysts · ~17 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.6 months
D/E 1.06 · 0% dilution
Lead: Phase 3
9 candidates
2 upcoming, next in ~1811d
N/A
A transparent, data-derived signal for AVENUE THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1M
Cash
$2.4M
Quarterly Burn
$438K
Runway
16.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| AJ201 | Phase 1 |
| atx-04 | Preclinical |
| avzo-021 | Phase 1/Phase 2 |
| avzo-023 | Phase 1/Phase 2 |
| BAER-101 | Preclinical |
| IV tramadol | Phase 3 |
| PIFPB block | N/A |
| RIFPB block | N/A |
| Tramadol | — |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
6
Total value held
$99K
| Holder | Shares | Value |
|---|---|---|
| boothbay fund management, llc | 41,089 | $82K |
| ubs group ag | 7,920 | $16K |
| wells fargo & company/mn | 500 | $1K |
| bank of america corp /de/ | 14 | $28 |
| sbi securities co., ltd. | 9 | $18 |
| concourse financial group securities, inc. | 0 | $0 |
Frequently asked questions
How many drug candidates are in AVENUE THERAPEUTICS, INC.'s pipeline?
AVENUE THERAPEUTICS, INC. (ATXI) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AVENUE THERAPEUTICS, INC.'s lead drug candidate?
AVENUE THERAPEUTICS, INC.'s most advanced tracked candidate is AJ201 (Phase 1) for Treatment of spinal and bulbar muscular atrophy (SBMA) (Kennedy's Disease).
What is AVENUE THERAPEUTICS, INC.'s next catalyst?
AVENUE THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SEGLENTIS" — expected June 3, 2031.
What is AVENUE THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AVENUE THERAPEUTICS, INC. has approximately 16.6 months of cash runway.
What is AVENUE THERAPEUTICS, INC.'s market capitalization?
AVENUE THERAPEUTICS, INC.'s market capitalization is approximately $1.1M.
Get the full picture on AVENUE THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.